3-Phosphoinositide-dependent protein kinase-1 (PDK1) plays a central role in activating the AGC subfamily of protein kinases. In particular, PDK1 plays an important role in the regulation of Akt/PKB survival pathway by phosphorylating Akt on Thr
Introduction
Many growth factors and cytokines have been reported to promote cell survival. The characterization of the survival signal transduction pathways stimulated by these factors has revealed that phosphatidylinositide-3-OH kinase (PI3K) promotes cell survival (Scheid et al., 1995; Cooper, 1995, 1996) . After growth factor stimulation, PI3K is activated and generates a phospholipid second messenger molecule, phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P 3 ), which induce the activation of several AGC subfamily of protein kinases (i.e., Akt/PKB, 70-kDa S6 kinase (p70 S6K ), 90-kDa ribosomal S6 kinases (RSKs), serumand glucocorticoid-inducible kinases (SGKs), and protein kinase C (PKC) isoforms).
The interaction of PtdIns(3,4,5)P 3 with the pleckstrin homology (PH) domain-containing serine/threonine kinase Akt recruits Akt to the plasma membrane, where Akt is phosphorylated at two key regulatory sites, Thr 308 and Ser 473 (Alessi et al., 1996) . Phosphorylation at both residues is necessary for full activation of Akt and the subsequent regulation of multiple cellular processes. Phosphorylation of Akt at Thr 308 was catalyzed by the ubiquitously expressed 3-phosphoinositide-dependent protein kinase-1 (PDK1), and the kinase responsible for phosphorylation of Akt at Ser 473 was called PDK2 (Alessi et al., 1997a,b; Stokoe et al., 1997; Stephens et al., 1998) . Another AGC subfamily of protein kinases are also activated by PtdIns(3,4,5)P 3 . The sequence similarity of the region surrounding Thr 308 of Akt revealed that PDK1 phosphorylates the equivalent residues of these kinases (reviewed by Vanhaesebroeck and Alessi, 2000) . Therefore, PDK1 plays a central role in the activation of the AGC subfamily members.
7-hydroxystaurosporine (UCN-01) was originally isolated as a selective PKC inhibitor from the culture broth of Streptomyces sp. (Takahashi et al., 1987 (Takahashi et al., , 1989 . Because UCN-01 exhibited the potent anti-tumor activity in in vivo and in vitro tumor models (Akinaga et al., 1991; Seynaeve et al., 1993) , its clinical usefulness has been investigated in the USA and Japan. UCN-01 possessed a unique ®ngerprint pattern in the in vitro anticancer drug-screening panel of the National Cancer Institute (Weinstein et al., 1997) . Although PKC family was thought to be a major target of UCN-01, it is still unclear whether PKC is the sole target of UCN-01 and how PKC inhibition is involved in its anti-tumor activity. Recently, Graves et al. (2000) reported that UCN-01 inhibits Chk1 kinase that is involved in the inactivation of Cdc25C by phosphorylating Ser 216 . However, there is the possibility that kinase(s) other than Chk1 kinase might also be the target of UCN-01, especially for the potentiation of cytotoxicity.
Screening the Akt inhibitory drugs revealed that UCN-01 possesses the ability to decrease the phosphoAkt level. We, thus, examined the eects of UCN-01 on upstream Akt kinases and found that UCN-01 directly suppressed upstream Akt kinase PDK1 with an IC 50 value of lower than 33 nM in in vitro and in vivo assays. Expression of PDK1 recovered Akt kinase activity. We thus concluded that PDK1 is one of the main target of UCN-01. Because UCN-01 exhibited the potent antitumor activity in in vivo and in vitro tumor models, the PDK1-Akt survival pathway might be a promising target for cancer chemotherapy. This hypothesis was supported by the fact that overexpression of active form of Akt diminished the cytotoxic eects of UCN-01.
Results

UCN-01 induces dephosphorylation and inactivation of Akt
Screening of the drugs that could interfere Akt kinase activity revealed that treatment of cells with UCN-01 decreased the amount of phosphorylated form of Akt. As shown in Figure 1a , Akt was phosphorylated at Ser 473 residue when COS-7, HT1080, and NL-17 cells were cultured in serum-containing medium. The addition of 0.3 and 1 mM UCN-01 induced the dephosphorylation of Akt within 1 h. UCN-01 also decreased the phospho-Akt level in human prostate PC-3, mouse ®broblast BALB/3T3, and 293T cells grown in serum-containing medium (data not shown). Heat shock is known to promote Akt phosphorylation in a PI3K-dependent manner (Shaw et al., 1998) . To examine the eects of UCN-01 on Akt phosphorylation, HT1080 cells were serum-starved for 24 h, and then incubated at 458C for 20 min. Consistent with the previous report (Shaw et al., 1998) , heat shock promoted the Akt phosphorylation at Ser 473 residue, and it could be prevented by pretreatment of HT1080 cells with 50 mM PI3K inhibitor LY294002 for 1 h. The pretreatment of 1 mM UCN-01 for 1 h also suppressed the heat shock-induced Akt phosphorylation. These results indicate that UCN-01 can inhibit Akt phosphorylation.
To con®rm that the dephosphorylation of Akt was associated with the decrease in Akt kinase activity, we measured the activity by immunoprecipitating FLAGtagged Akt from 293T cells that had been transfected with the FLAG-tagged WT-akt cDNA. Pretreatment of the cells with staurosporine, UCN-01, and LY294002, but not the PKC inhibitor calphostin C, suppressed Akt kinase activity (Figure 1c ). The Akt inactivation was also consistent with phospho-Akt (Thr 308 ) level decrease (Figure 1c, inset) . Bad was known to be phosphorylated by Akt at Ser 136 (Vanhaesebroeck and Alessi, 2000) . Thus, we transfected glutathione-S-transferase (GST)-tagged bad cDNA together with the Myc-and (His) 6 -epitope tagged WT-mouse akt1 cDNA into 293T cells. After serum starvation for 24 h, the transfected cells were cultured in serum-free medium containing UCN-01 for the last 2 h of incubation. As shown in Figure 1d , UCN-01 decreased the phospho-Bad (Ser 136 ) level in a dose-dependent manner. We also found that UCN-01 could inhibit the phosphorylation of glycogen synthase kinase-3a (GSK-3a) at Ser 21 residue (data not shown). These results suggest that UCN-01 suppressed Akt kinase activity in vivo.
We then compared the eect of UCN-01 on phospho-Akt (Thr 308 ) levels with that of UCN-02 (stereoisomer of UCN-01; Takahashi et al., 1989) and staurosporine ( Figure 1e ). 293T cells were transfected with the FLAG-tagged WT-akt cDNA. Then 293T cells were treated with UCN-01 in serum-containing medium. The treatment of 1 and 0.1 mM UCN-01 completely inhibited the phosphorylation of Akt within 1 h, while 0.1 mM staurosporine had little eects. UCN-02, up to 1 mM, could not decrease phospho-Akt level. These results indicate that UCN-01, among the staurosporine analogs, is a potent inhibitor of Akt phosphorylation.
Although the PKC family has long been thought to be a major target of UCN-01 (Takahashi et al., 1987 (Takahashi et al., , 1989 , it is still unclear whether PKC inhibition is involved in its anti-tumor activity. Since the a-, b-, and g-adducins have been reported to be PKC substrates (Matsuoka et al., 1998) , we assessed the inhibitors' eects on PKC by the dephosphorylation of adducin using an anti-phospho-adducin antibody (Figure 1e ). The exposure to 1 mM staurosporine almost completely down-regulated the phospho-adducin level in 293T cells, while the same concentration of UCN-01 and UCN-02 had little eect. This result suggests that, among the inhibitors of PKC, staurosporine is the most potent and that, in 293T cells, Akt dephosphorylation might not result from PKC inactivation. These results were supported by the observations that another speci®c PKC inhibitor, calphostin C (Kobayashi et al., 1989), had no eects on Akt phosphorylation ( Figure 1c ) and that the PKC activator phorbol 12-myristate 13-acetate (TPA) had no eects on Akt phosphorylation in 293T cells (data not shown). These results indicate that the inhibition of PKC might not be the main reason for the anti-tumor activity of UCN-01.
UCN-01 induces apoptosis with caspase activation
Akt was known to be an important molecule transmitting survival signals (Vanhaesebroeck and Alessi, 2000) . Because UCN-01 could suppress Akt kinase activity, treatment of cells with UCN-01 might lead the cells to undergoing apoptosis. The apoptotic cells were evaluated by staining with propidium iodide followed by examining the appearance of sub-G 1 population using¯ow cytometry. UCN-01 treatment increased the number of apoptotic sub-G 1 fraction of HT1080 cells cultured in serum-containing medium for 18 h (data not shown). We further examined the activity of caspase-3 (-like) proteases in the UCN-01-treated HT1080 cells using¯uorogenic-labeled tetrapeptides acetyl-L-aspartyl-L-glutamyl-L-valyl-L-aspart-7-amino-4-methylcoumarin (DEVD-AMC). UCN-01 promoted the activation of caspase-3 (-like) proteases ) antibody or an anti-Akt antibody. (c) 293T cells were transfected with pFLAG-CMV-2 vector encoding WT-Akt. After incubation for 24 h in serumcontaining medium, the transfected cells were treated with vehicle, 1 mM staurosporine, 1 mM UCN-01, 1 mg/ml of calphostin C, or 50 mM LY294002 in serum-containing medium for 1 h. Cells were harvested and lysed in lysis buer. The FLAG-tagged Akt was immunoprecipitated and was subjected to Akt kinase assay, as described in Materials and methods. The vertical bars represent s.d. value of triplicate determinations. The immunoprecipitated proteins were also subjected to immunoblot analysis with an antiphospho-Akt (Thr 308 ) antibody (inset). (d) 293T cells were transfected with pEBG vector containing mouse bad cDNA (pEBGMBad) together with empty pUSEamp vector (Mock) or pUSEamp vector containing mouse WT-akt cDNA (WT-mAkt). After transfection for 24 h, medium was replaced with serum-free medium. After incubation for further 24 h, transfected cells were treated with UCN-01 in serum-free medium for 2 h. Cells were harvested and lysed in lysis buer. The cell lysates were electrophoresed and immunoblotted with an anti-phospho-Bad (Ser In some experiments, cells were further treated with 100 mg/ml of the caspase inhibitor Z-Asp or Z-VAD. Cells were harvested, and the increase in the activity of caspase-3 proteases in the HT1080 cell lysates was determined using DEVD-AMC as the substrate. The vertical bars represent s.d. value of triplicate determinations. The HT1080 and 293T cell lysates were also electrophoresed and immunoblotted with an anti-cleaved D4-GDI antibody, an anti-cleaved PARP antibody, or an anti-PARP antibody in HT1080 cells in a dose-dependent manner ( Figure  1f ). Activation was suppressed by adding caspase inhibitors, benzyloxycarbonyl-Asp-CH 2 OCO-2,6,-dichlorobenzene (Z-Asp) and benzyloxycarbonyl-ValAla-Asp-CH 2 OCO-2,6,-dichlorobenzene (Z-VAD). To clarify the activation of caspase-3 in vivo in HT1080 cells after UCN-01 treatment, we performed Western blot analysis using antibodies speci®cally recognizing the p23 cleaved fragment of D4-GDI or the p85 cleaved fragment of poly(ADP-ribose) polymerase (PARP). The 28-kDa D4-GDI was cleaved by caspase-3 to produce the 23-and 5-kDa cleaved fragments Na et al., 1996) . PARP was also one of the substrates of caspase-3 and produced the 85-kDa fragment after caspase-3-mediated cleavage (Nicholson et al., 1995; Tewari et al., 1995) . UCN-01 treatment increased the amount of cleaved fragment of both D4-GDI and PARP ( Figure  1f ), suggesting that caspase-3 is activated in vivo in HT1080 cells after UCN-01 treatment. Moreover, UCN-01 induced 293T cell apoptosis with caspase-3 activation in a dose-dependent manner ( Figure 1f ). These results suggest that UCN-01 can initiate the cells to undergo apoptosis by probably interruption of the Akt-mediated survival pathway.
The effect of UCN-01 on kinase activities of PI3K and Akt
There are two possibilities for the mechanism by which UCN-01 suppressed Akt phosphorylation and activation. First, UCN-01 decreased Akt kinase activity by inhibiting the PI3K responsible for translocation to the plasma membrane and conformational change of Akt. Second, UCN-01 down-regulated upstream Akt kinases that were involved in the phosphorylation of Akt on Thr 308 and Ser 473 residues. We ®rst examined the change of PI3K kinase activity after UCN-01 treatment. We transfected HA-tagged PI3K p110a subunit cDNA into 293T cells. After incubation for 24 h, cells were treated with UCN-01 in serum-containing medium for 1 h. The PI3K p110a subunit was immunoprecipitated from the cell lysates. No change of PI3K kinase activity was observed ( Figure 2a ). We also examined the eect of UCN-01 on the endogenous PI3K kinase activity by immunoprecipitating PI3K from 293T cells cultured in serum-containing medium using an antiphospho-tyrosine antibody (PY20). Treatment of UCN-01 did not change the endogenous PI3K kinase activity (data not shown). To examine the direct eects of UCN-01 on PI3K kinase activity, immunoprecipitated active PI3K p110a protein or its kinase-de®cient PI3K p110a protein was incubated with 0.1 or 1 mM UCN-01 for 20 min at 308C and was then subjected to PI3K kinase assay in the presence of UCN-01 or LY294002. As shown in Figure 2b , UCN-01 did not inhibit PI3K kinase activity in vitro, though preincubation of PI3K with 50 mM LY294002 suppressed its kinase activity. When 293T cells were transfected with active PI3K p110a subunit cDNA (active), we observed the increase in Akt kinase activity and phospho-Akt level (Figure 2c ), as reported (Didichenko et al., 1996) . The transfection of kinase-de®cient PI3K p110a subunit cDNA (KD) could not stimulate Akt activation. UCN-01 treatment for 1 h decreased the phospho-Akt (Thr 308 ) level, and the overexpression of active PI3K could not recover the decrease. These results indicate that PI3K is not the target of UCN-01.
We then examined the second possibility that UCN-01 down-regulated upstream Akt kinases that could phosphorylate Akt at Thr 308 and Ser 473 residues. Akt itself were reported to be associated with phosphorylation of Akt on Ser 473 (Toker and Newton, 2000) . We obtained recombinant human active Akt protein, which had previously been activated by PDK1. The active Akt protein was incubated with UCN-01 for 10 min in vitro before estimating its kinase activity. Our estimation of the eects of UCN-01 on Akt kinase activity revealed that UCN-01 inhibited activity with an IC 50 value of about 500 nM ( Figure 2d ). This result indicates that UCN-01-mediated Akt dephosphorylation and inactivation is not the cause of direct inhibition of Akt kinase activity.
Identification of PDK1 as a target of UCN-01
PDK1 was originally identi®ed as the kinase responsible for phosphorylation of Akt at Thr 308 (Alessi et al., 1997a,b; Stokoe et al., 1997; Stephens et al., 1998) . PDK1 was also reported to be associated with the Akt phosphorylation at the Ser 473 residue by interacting with the fragment of PRK2 (Balendran et al., 1999) . To examine the change of PDK1 kinase activity, 293T cells were treated with inhibitors in serum-containing medium for 1 h. Then, endogenous PDK1 protein was immunoprecipitated and subjected to PDK1 kinase assay. We found that staurosporine and UCN-01 suppressed PDK1 kinase activity within 1-h treatment (Figure 3a) . Calphostin C and LY294002 had no eects on PDK1 kinase activity. UCN-01 suppressed the kinase activity of endogenous PDK1 proteins that were immunoprecipitated from 293T in a dose-dependent manner and with an IC 50 value of about 33 nM ( Figure  3b ). To assess the direct eects of UCN-01 on PDK1, recombinant PDK1 protein was incubated in vitro with UCN-01 for 30 min at 308C. As shown in Figure 3c (open circles), UCN-01 directly inhibits PDK1 with an IC 50 value of about 33 nM. These results indicate that PDK1 is a target of UCN-01 and PDK1 inhibition is involved in UCN-01-mediated Akt dephosphorylation and inactivation.
It is now clear that PDK1 plays a central role in the activation of the AGC subfamily of protein kinases (Vanhaesebroeck and Alessi, 2000) . PDK1 phosphorylates all members of the AGC kinases at residues equivalent to Thr 308 (known as activation loop or Tloop) of Akt. PDK1 is also a member of the AGC subfamily of protein kinases. PDK1 phosphorylates itself at the activation loop of PDK1 (Ser 241 ), resulting in its own activation . The autophosphorylation of PDK1 was promoted by incubation of PDK1 with phosphorylated RSK2 PDK1 inhibitor UCN-01 S Sato et al (90 kDa ribosomal S6 kinase-2) peptide (pSer386 peptide) but not with non-phosphorylated RSK2 peptide (Ser386 peptide) (Frodin et al., 2000) . Thus, we examined the eects of UCN-01 on autophosphorylation of PDK1. COS-7 cells were transfected with the Myc-tagged WT-PDK1 cDNA. After serum starvation for 4 h, cells were harvested and solubilized. The Myc-tagged PDK1 was immunoprecipitated and incubated with UCN-01 in the presence of pSer386 peptide for 20 min at 238C, following PDK1 kinase assay. As shown in Figure 3d , autophosphorylation of PDK1 was promoted by pSer386 peptide but not by Ser386 peptide. Addition of UCN-01 suppressed the autophosphorylation of PDK1 induced by pSer386 peptide (Figure 3d ), indicating that UCN-01 directly inhibits PDK1 kinase activity. We then examined the change of the kinase activity of p70 S6K which was known to be phosphorylated and activated by PDK1 (Vanhaesebroeck and Alessi, 2000) . HT1080 cells were treated with UCN-01 for 1 h and then harvested. p70 S6K protein was immunoprecipitated and was subjected to p70 S6K kinase assay. As shown in Figure  3e , treatment of the cells with UCN-01 suppressed p70 S6K kinase activity in a dose-dependent manner. When recombinant active SGK and p70 S6K proteins were incubated with UCN-01 in vitro, UCN-01 had marginal eects on their kinase activities (Figure 3c , open triangles and closed circles, respectively). Therefore, the decrease in p70 S6K kinase activity in cells (Figure 3e ) might be caused by inhibiting PDK1 kinase After transfection for 24 h, cells were treated with UCN-01 in serum-containing medium for 1 h. The HAtagged PI3K p110a subunit was immunoprecipitated and was subjected to PI3K kinase assay, as described in Materials and methods. The lipid fractions were resolved by TLC following autoradiography (top panel). The amount of immunoprecipitated HAtagged p110 protein was con®rmed by immunoblot analysis with an anti-HA antibody (bottom panel). (b) 293T cells were transfected with empty pcDNA3 vector or pcDNA3 vector containing PI3K p110aCAAX or PI3K p110aCAAX-KD cDNA. After transfection for 24 h, cells were harvested and lysed in lysis buer. The immunoprecipitated HA-tagged PI3K p110aCAAX (Active) or PI3K p110aCAAX-KD (KD) protein was incubated with buer alone, the indicated concentrations of UCN-01, or 50 mM LY294002 for 20 min at 308C, following PI3K kinase assay in the presence of UCN-01 or LY294002, as described in Materials and methods. The lipid fractions were resolved by TLC following autoradiography. (c) 293T cells were transfected with pFLAG-CMV-2 vector encoding WT-Akt together with empty pcDNA3 vector (Mock) or pcDNA3 vector containing PI3K p110aCAAX (Active) or PI3K p110aCAAX-KD (KD) cDNA. After transfection for 24 h, cells were incubated with (+) or without (7) UCN-01 in serumcontaining medium. After incubation for 1 h, cells were harvested and lysed in lysis buer. The immunoprecipitated FLAG-tagged Akt was subjected to Akt kinase assay, as described in Materials and methods. The immunoprecipitated proteins were also subjected to immunoblot analysis with an anti-phospho-Akt (Thr we examined the eect of UCN-01 on PDK1 kinase activity in vivo using xenografted murine NL-17 and human PC-3 tumors. The intraperitoneal administration of UCN-01 (5 and 10 mg/kg) suppressed the PDK1 kinase activity in NL-17 cells xenografted into BALB/c mice (Figure 4a ). The intravenous injection of UCN-01 (6, 9, and 13.5 mg/kg) also suppressed the PDK1 kinase activity in PC-3 cells xenografted into nude mice (Figure 4b) . At 48 h after the UCN-01 administration, the PDK1 kinase inhibition was After further incubation for 20 min at 238C, the reactions were stopped, electrophoresed, and visualized by autoradiography. (e) HT1080 cells were treated with UCN-01 in serum-containing medium. After incubation for 1 h, cells were harvested and lysed in lysis buer. p70 S6K protein was immunoprecipitated and was subjected to S6 kinase assay, as described in Materials and methods. The vertical bars represent s.d. value of triplicate determinations diminished. In several tumor xenografts, UCN-01 exhibited its anti-tumor activity when UCN-01 was administrated intraperitonealy (5 and 10 mg/kg; Akinaga et al., 1991; Abe et al., 2001) or intravenously (6, 9, and 13.5 mg/kg; Kurata et al., 1999) . These results strongly indicate that PDK1 is the target of UCN-01 both in vitro and in vivo.
Expression of active-form of Akt overcomes UCN-01-mediated cytotoxicity
To con®rm that the inhibition of PDK1 kinase activity was the main reason for Akt dephosphorylation after UCN-01 treatment, we estimated the phospho-Akt (Thr 308 ) amount in UCN-01-treated 293T cells that had been transfected with Myc-tagged WT-PDK1 cDNA or KD-PDK1 cDNA . Treatment of UCN-01 for 1 h decreased the phospho-Akt (Thr  308 ) level in mock-or KD-PDK1-transfected 293T cells in a dose-dependent manner (Figure 5a ), whereas overexpression of WT-PDK1 restored the phospho-Akt (Thr 308 ) level (Figure 5a ), but not the phospho-Akt (Ser 473 ) level (data not shown). We then examined the eects of WT-PDK1 overexpression on UCN-01-induced apoptosis. We transfected Myc-tagged WT-PDK1 cDNA into PC-3 cells, following incubation with UCN-01 in serum-containing medium for 6 h. Overexpression of WT-PDK1, however, could not suppress the UCN-01-induced caspase-3 activation (data not shown). Because long-time exposure of cells to UCN-01 completely inhibited the activity of both transfected and endogenous PDK1 (Figure 5b) , transfection of PDK1 cDNA could not restore the Akt-mediated survival.
Then, we examined the eects of UCN-01 on HT1080 cells overexpressing active form of Akt (myrAkt). Tagging Akt with c-src-derived residues required for myristoylation was reported to result in the constitutive targeting of myr-Akt to the plasma membrane (Kohn et al., 1996) . The myr-Akt was more phosphorylated at both Thr 308 and Ser 473 residues than WT-Akt did in HT1080 cells (Figure 5c ). Treatment of the cells with 1 mM UCN-01 for 5 h induced caspasemediated cleavage of PARP, but it was suppressed by overexpressing myr-Akt but not by WT-Akt overexpression. Measurement of caspase-3 activity also showed that overexpression of myr-Akt inhibited the activation of caspase-3 (Figure 5d ). For control experiments, the transfected HT1080 cells were treated with VP-16 (etoposide) because short-time treatment of VP-16 did not decrease the phospho-Akt level ( Figure  5c ). When the transfectants were treated with VP-16 (30 mg/ml) for 5 h, the caspase-mediated cleavage of PARP was similarly occurred in both WT-Akt transfectants and in myr-Akt transfectants ( Figure  5c ). These results suggested that turn-o of PDK1-Akt survival pathway may in part be involved in the cytotoxic eects of UCN-01.
Discussion
The susceptibility of cells to undergo chemotherapyinduced apoptosis appears to be dependent on the balance between pro-apoptotic and anti-apoptotic signals. Therefore, it is possible to consider that chemotherapeutic agents may induce apoptosis not only by increasing pro-apoptotic signal but also by decreasing anti-apoptotic signal such as the Akt survival pathway. Recent reports indicated that the inhibition of the Akt survival pathway is linked to the cytotoxic eects of some drugs (Hsu et al., 2000; Nakashio et al., 2000; Fujita et al., 2002) . To clarify which drugs exhibit their cytotoxicity by inhibiting this survival pathway, we screened anti-tumor drugs that could down-regulate the phospho-Akt level. We found that treating cells with UCN-01 and staurosporine could decrease the phospho-Akt level in cells (Figure 1 ). (b) PC-3 xenograft was established by inoculation of cultured cells into BALB/c-nu/nu mice. UCN-01 was administrated intravenously at doses of 0, 6, 9, or 13.5 mg/kg. After 24-or 48-h of administration, the tumor was resected and was subjected as described in (a) UCN-01 was originally isolated as a PKC-selective inhibitor (Takahashi et al., 1987 (Takahashi et al., , 1989 . UCN-01 exhibited the potent anti-tumor activity in several in vivo and in vitro tumor models (Akinaga et al., 1991; Seynaeve et al., 1993) . It possesses a unique ®ngerprint pattern referred to as`compare negative' in the in vitro anticancer drug-screening panel of the National Cancer Institute (Weinstein et al., 1997) . Therefore, its clinical investigations have been initiated in the USA and Japan. Although PKC family has long been thought to be a major target of UCN-01, it is still unclear whether PKC inhibition is involved in its anti-tumor activity. The a-, b-, and g-adducins were reported to be PKC substrates (Matsuoka et al., 1998) . The PKC-inhibitory eect of UCN-01 was weaker than that of staurosporine (Figure 1e ), as reported previously (Takahashi et al., 1989) . However, the Akt-inhibitory eect of UCN-01 was stronger than that of staurosporine. These results suggest that the inhibition of PKC may not be the main reason for the Akt-inhibitory eect of UCN-01. The facts that other speci®c PKC inhibitor calphostin C (Kobayashi et al., 1989) had no eects on Akt phosphorylation (Figure 1c ) and that PKC activator TPA had no eects on Akt phosphorylation in 293T cells (data not shown) also suggested that PKC inhibition might not be involved in Akt dephosphorylation and inactivation, although further studies are needed. Because several groups have been suggested that induction of apoptosis is intrinsically linked to the cytotoxic eect of UCN-01 (Wang et al., 1995; Shao et al., 1997; Sugiyama et al., 1999) , we have investigated whether Akt inhibition is linked to antitumor activity of UCN-01.
The akt gene was originally identi®ed as the cellular counterpart of the retroviral oncogene v-akt, which was present in AKT8, a retrovirus that caused T-cell lymphoma in mice. The catalytically inactive Akt exists in the cytosol. By activation of PI3K, PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 are synthesized at the plasma membrane and Akt is recruited to the plasma membrane. Interaction of Akt to the lipids induces a conformational change of Akt. Then Akt is phosphory- . After transfection for 24 h, medium was replaced to serum-free medium. After incubation for further 24 h, cells were treated with DMSO control, 1 mM UCN-01, or 30 mg/ml of VP-16 in serum-free medium for 5 h. Then cells were harvested and lysed in lysis buer. The cell lysates were electrophoresed and were subjected to immunoblot analysis with the indicated antibodies. (d) HT1080 cells were treated as described in (c). Cells were harvested, and the increase in the activity of caspase-3 proteases in the cell lysates was determined using DEVD-AMC as the substrate. Alessi, 2000) . Recently, Balendran et al. (1999) reported that interaction of the fragment of protein kinase C-related kinase-2 (PRK2) with PDK1 converted PDK1 from a kinase that could phosphorylate only Thr 308 residue of Akt to one that could phosphorylate both Thr 308 and Ser 473 residues. Akt itself was also reported to be associated with the Akt phosphorylation at the Ser 473 residue (Toker and Newton, 2000) . Moreover, integrin-linked kinase (ILK) was reported to be associated with phosphorylation of Akt on Ser 473 (Delcommenne et al., 1998) . Dual phosphorylation at both residues is necessary for full activation of Akt. Akt mediates many PI3K-regulated biological responses including glucose uptake and protein synthesis. The activated Akt was also reported to suppress apoptosis by phosphorylating the pro-apoptotic Bcl-2 family member Bad at Ser 136 , caspase family member caspase-9 at Ser 196 , and the Forkhead transcription factor protein family (Vanhaesebroeck and Alessi, 2000) .
UCN-01 induced the dephosphorylation of Akt (Figure 1) . Estimation of the change of Akt kinase activity also revealed that the treatment of cells with UCN-01 down-regulated Akt kinase activity in cells (Figure 1c) . These results were supported by the facts that UCN-01 suppressed the phosphorylation of Akt substrates, Bad and GSK-3 in cells (Figure 1d and data not shown). However, UCN-01 could not directly inhibit Akt kinase activity in vitro (Figure 2d) . Therefore, UCN-01 might suppress upstream Akt kinase to induce dephosphorylation and inactivation of Akt. Following three results indicated that PI3K is not the target of UCN-01. First, PI3K kinase activity was not aected by UCN-01 in cells ( Figure 2a) ; second, UCN-01 had no direct eects on PI3K kinase activity in vitro ( Figure 2b) ; third, transfection of active-PI3K (p110CAAX) could not recover the UCN-01-induced Akt dephosphorylation (Figure 2c ). We found that PDK1 inactivation was the main reason for the UCN-01-induced Akt inactivation and dephosphorylation (Figure 3) .
It is now clear that PDK1 plays a central role in the activation of the AGC subfamily of protein kinases. PDK1 phosphorylates all members of the AGC kinases at residues equivalent to Thr 308 (known as activation loop or T-loop) of Akt (Vanhaesebroeck and Alessi, 2000) . Measurement of p70 S6K kinase activity suggests that UCN-01 also suppressed kinase activity of p70 S6K that was immunoprecipitated from UCN-01-treated cells (Figure 3e ). However, UCN-01 had marginal direct eects on the kinase activities of recombinant active SGK and p70 S6K proteins (Figure 3c ). PDK1 is also a member of the AGC subfamily of protein kinases. PDK1 phosphorylates itself at the activation loop of PDK1 (Ser 241 ) which results in its own activation . UCN-01 suppressed the autophosphorylation of PDK1 in vitro (Figure 3d ). Because the expression of WT-PDK1, but not KD-PDK1, suppressed dephosphorylation and inactivation of Akt induced by UCN-01 (Figure 5a ), PDK1 is one of the main targets of UCN-01. Our data is consistent with the previous report that 1 mM UCN-01 could suppress PDK1 kinase activity in vitro (Davies et al., 2000) . The fact that overexpression of constitutive active Akt (myr-Akt) suppressed the cytotoxicity of UCN-01 (Figure 5d ) indicated that UCN-01 may exhibit its cytotoxicity in part by turn o of the PDK1-Akt survival pathway.
Recently, several reports including ours indicate that K252c and KT5720 (Davies et al., 2000) , staurosporine analogs (Hill et al., 2001) , topotecan (Nakashio et al., 2000) , N-a-tosyl-L-phenylalanyl chloromethyl ketone (TPCK; Ballif et al., 2001) , and Hsp90 inhibitors (Fujita et al., 2002) have the ability to interfere PDK1 signaling directly or indirectly. Because our ®ndings suggested that inhibiting PDK1-Akt survival pathway is linked to its cytotoxicity, these agents might exhibit their cytotoxicity by interfering PDK1-Akt signaling pathway.
When cells were treated with UCN-01, we observed the dephosphorylation of Akt at both Thr 308 and Ser 473 residues ( Figure 1 ). The UCN-01-mediated decrease in phospho-Akt (Thr 308 ) level might be explained by the direct inactivation of PDK1. Since UCN-01 could not directly interfere Akt kinase activity (Figure 2d) Several experiments suggest that the Akt-mediated survival pathway is an attractive target for cancer chemotherapy (Sellers and Fisher, 1999) . First, the Akt pathway is relatively inactive in resting cells; second, ampli®cation of the akt gene occurs in some tumors; third, loss of the tumor suppressor PTEN is common in tumors and its loss constitutively activates Akt. Our results demonstrate that UCN-01 suppresses Akt pathway by directly antagonizing PDK1 kinase activity. Because UCN-01 has already proved to have potent anti-tumor activity in vivo and in vitro (Akinaga et al., 1991; Seynaeve et al., 1993) , Akt-PDK1 pathway may be a promising target for tumor treatment.
Materials and methods
Reagents
The recombinant human active PDK1, active Akt1, inactive SGK, active SGK (D1-60, S422D), and active p70 S6K (T412E) proteins were obtained from Upstate Biotechnology (Lake Placid, NY, USA). LY294002 was purchased from Sigma (St. Louis, MO, USA). Staurosporine and calphostin C were obtained from Wako Pure Chemicals (Tokyo, Japan). UCN-01 and UCN-02 (stereoisomer of UCN-01) were kindly provided by Kyowa Hakko Kogyo (Tokyo, Japan). VP-16 (etoposide) was kindly provided by Bristol Meyers-Squibb (Tokyo, Japan).
Cell culture conditions
Human embryonic kidney 293T, human ®brosarcoma HT1080, African green monkey kidney COS-7, and mouse colon adenocarcinoma NL-17 cells were cultured in DMEM medium supplemented with 10% FBS. Human prostate cancer PC-3 cells were cultured in Ham's F12 medium supplemented with 7% FBS. In some experiments, cells were precultured for 24 h in serum-free medium (serum starvation) before drug treatment. Some cells were serum-starved for 24 h, following incubation at 458C for 20 min (heat shock).
Plasmids
Human wild-type akt1 cDNA (WT-Akt) in a pFLAG-CMV-2 vector (Sigma) or a pHM6 vector (Roche Molecular Biochemicals, Mannheim, Germany) were established in our laboratory Sato et al., 2000) . The Mycand (His) 6 -epitope tagged wild-type mouse akt1 cDNA (WTmAkt) and NH 2 -terminal myristoylated active mouse akt1 cDNA (myr-mAkt) in a pUSEamp vector were purchased from Upstate Biotechnology. The GST-tagged mouse bad cDNA (GST-mBad) in a pEBG vector was obtained from New England Biolabs (Beverly, MA, USA). The HA-tagged PI3K p110a subunit cDNA, PI3K p110a subunit cDNA containing membrane-targeting CAAX motif (active-PI3K), and its inactive mutant cDNA (KD-PI3K) in pcDNA3 vectors were kindly provided by Dr M Thelen (Istituto di Ricerca in Biomedicina, Switzerland) (Didichenko et al., 1996) . The Myc-tagged human full-length PDK1 cDNA (WT-PDK1) in a pCMV3 vector was kindly provided by Drs P Hawkins and K Anderson (The Babraham Institute, UK) . The kinase-de®cient PDK1 mutant cDNA (KD-PDK1) was generated by converting codon encoding Asp 223 to Ala codon using the QuickChange sitedirected mutagenesis kit (Stratagene, La Jolla, CA, USA). All the plasmid DNAs for transfection were puri®ed using a Qiagen plasmid Maxi kit according to the manufacturer's protocol (Qiagen, Chatsworth, CA, USA).
Transient transfection, immunoprecipitation, and Western blot analysis
Cells were transfected with appropriate plasmids using Superfect transfection reagent (Qiagen) or LipofectAMINE 2000 reagent (Gibco Laboratories, Grand Island, NY, USA) according to the manufacturers' instructions.
For immunoprecipitation, cells were harvested and solubilized in lysis buer for immunoprecipitation (20 mM Tris-HCl pH 7.5, 0.2% Nonidet P-40, 10% glycerol, 1 mM EDTA, 1.5 mM magnesium chloride, 137 mM sodium chloride, 50 mM sodium¯uoride, 1 mM sodium vanadate, 12 mM bglycerophosphate, 1 mM PMSF, and 1 mM aprotinin) . FLAG-tagged proteins were immunoprecipitated with an agarose conjugated with an anti-FLAG M2 monoclonal antibody (mAb) (anti-FLAG M2 agarose; Sigma). HA-tagged proteins were immunoprecipitated with an agarose conjugated with an anti-HA mAb (clone F-7) (anti-HA agarose; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Myc-tagged proteins were immunoprecipitated with an agarose conjugated with an anti-Myc mAb (clone 9E10) (anti-Myc agarose; Santa Cruz Biotechnology).
For 
In vitro kinase assay
Akt kinase activity of the immunoprecipitated FLAG-tagged Akt was estimated using an Akt kinase assay kit according to the manufacturer's instructions (Upstate Biotechnology). Brie¯y, the immunoprecipitated Akt was incubated with GSK-3 peptide (RPRAATF) as a substrate for 10 min at 308C in the presence of 112.5 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP. In some experiments, recombinant human active Akt (Upstate Biotechnology) was preincubated with UCN-01 for 10 min at 308C. Then kinase reaction was started by adding 112.5 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP, as described above.
PI3K kinase activity was determined, as previously described (Didichenko et al., 1996) . Brie¯y, 293T cells were transfected with pcDNA3-p110a. After transfection for 24 h, cells were treated with UCN-01 for 1 h in serum-containing medium. The HA-tagged p110a was immunoprecipitated with an agarose conjugated with an anti-HA agarose and was then subjected to PI3K assay in the presence of 55 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP, as described previously (Didichenko et al., 1996) . In some experiments, the endogenous PI3K was immunoprecipitated with the agarose conjugated with an anti-phosphotyrosine (PY20) antibody (Transduction Laboratories). To examine the direct eects of UCN-01 on PI3K kinase activity, we transfected pcDNA3-p110aCAAX and pcDNA3-p110aCAAX-KD into 293T cells. Then HA-tagged p110a-CAAX or p110a-CAAX-KD protein was immunoprecipitated with an agarose conjugated with an anti-HA agarose following in vitro incubation with UCN-01 or LY294002 for 20 min at 308C. The immunoprecipitated PI3K was then subjected to PI3K assay in the presence of these drugs, as described above.
We measured PDK1 kinase activity using a PDK1 kinase assay kit according to the manufacturer's instructions (Upstate Biotechnology). Brie¯y, 293T cells were incubated with inhibitors in serum-containing medium for an appropriate time and then harvested. The cell lysates were incubated with protein G agarose conjugated with an anti-PDK1 antibody (Upstate Biotechnology). The immunoprecipitated PDK1 was ®rstly incubated with inactive SGK for 30 min at 308C. In some experiments, recombinant human active PDK1 (Upstate Biotechnology) was incubated with inactive SGK for 30 min at 308C in the presence of UCN-01. Then the PDK1-dependent SGK kinase activity was estimated by incubating with GSK-3 peptide (RPRAATF) as a substrate for 10 min at 308C in the presence of 90 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP. To estimate the autophosphorylation of PDK1, COS-7 cells were transfected with pCMV3-PDK1. After transfection for 24 h, cells were serum-starved for 4 h and then harvested. The immunoprecipitated Myc-tagged PDK1 was incubated with 10 mM peptide of mouse RSK2 (residues 373 ± 396), Ser386 peptide (KKPPSANAHQLFRGFSFVAITSDDE) or pSer386 peptide (KKPPSANAHQLFRGF(phospho-S)FVAITSDDE), in the presence or the absence of UCN-01 for 20 min at 238C. The autophosphorylation of PDK1 was started by adding 20 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP. After incubation for 20 min at 238C, the reactions were electrophoresed and visualized by autoradiography (Frodin et al., 2000) .
We measured p70 S6K kinase activity using an S6 kinase assay kit according to the manufacturer's instructions (Upstate Biotechnology). Brie¯y, 293T cells were treated with UCN-01 in serum-containing medium for 1 h and then harvested. The cell lysates were incubated with protein G agarose conjugated with an anti-p70 S6K antibody (Upstate Biotechnology). The immunoprecipitated p70 S6K protein was incubated with a substrate peptide (AKRRRLSSLRA) for 10 min at 308C in the presence of 90 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP. In some experiments, recombinant human active p70 S6K (T412E; Upstate Biotechnology) was ®rstly incubated with UCN-01 for 10 min at 308C, and then reacted to a substrate peptide (AKRRRLSSLRA) for 10 min at 308C in the presence of 90 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP. We examined the change of SGK kinase activity after UCN-01 treatment using a PDK1 kinase assay kit as descrived above. Brie¯y, recombinant human active SGK (D1-60, S422D; Upstate Biotechnology) was ®rstly incubated with UCN-01 for 10 min at 308C and was then reacted to GSK-3 peptide (RPRAATF) as a substrate for 10 min at 308C in the presence of 90 mM ATP (®nal concentration) containing 15 mCi [g-32 P]ATP, as described above.
Evaluation of PDK1 kinase activity in tumor xenografts
NL-17 cells were inoculated subcutaneously into the right anks of BALB/c mice (Charles River, Kanagawa, Japan). Alternatively, PC-3 cells were inoculated subcutaneously into the right¯anks of BALB/c-nu/nu mice (Charles River). UCN-01 was administrated intraperitonealy or intravenously. The tumors were resected at the appropriate time intervals after the UCN-01 administration. The tumor cell lysates were incubated with protein G agarose conjugated with an anti-PDK1 antibody. The immunoprecipitated PDK1 was subjected to PDK1 kinase assay, as described above.
Estimation of apoptosis
The caspase activity in the cell lysates was measured, as described previously (Fujita et al., 1998) .
